Table 5.
Vitamin D Deficiency and Clinical Factors Associated With Live Birth in PPCOSII
| OR | 95% CI | AOR a | 95% CI | P | |
|---|---|---|---|---|---|
| Vitamin D status | 0.04 | ||||
| 25(OH)D ≥ 20 | 1.00 | — | 1.00 | — | |
| 25(OH)D < 20 | 0.54 | 0.37–0.8 | 0.63 | 0.41–0.98 | |
| Age | 0.95 | 0.91–0.99 | 0.94 | 0.9–0.99 | 0.01 |
| Race | 0.6 | ||||
| White | 1.00 | — | 1.00 | — | |
| Black | 0.92 | 0.53–1.58 | 1.1 | 0.61–2.0 | |
| Other | 0.65 | 0.26–1.61 | 0.64 | 0.25–1.7 | |
| BMI | 0.0003 | ||||
| <30 | 1.00 | — | 1.00 | — | |
| 30+ | 0.4 | 0.27–0.58 | 0.33 | 0.23–0.58 | |
| Treatment | 0.005 | ||||
| Letrozole | 1.00 | — | 1.00 | — | |
| Clomiphene | 0.63 | 0.43–0.91 | 0.57 | 0.39–0.84 | |
| HOMA IR categories of insulin resistance | 0.5 | ||||
| Normal | 1.00 | — | 1.00 | — | |
| Moderate | 0.71 | 0.44–1.14 | 1.4 | 0.79–2.4 | |
| Severe | 0.57 | 0.36–0.89 | 1.1 | 0.62–1.9 | |
| Quartiles of total testosterone, ng/dL | 0.04 | ||||
| Q1 (4–33.1) | 1.00 | — | 1.00 | — | |
| Q2 (33.2–49.3) | 0.67 | 0.41–1.1 | 0.64 | 0.38–1.1 | |
| Q3 (49.5–66.) | 0.69 | 0.41–1.16 | 0.73 | 0.42–1.3 | |
| Q4 (66.7–226) | 0.43 | 0.25–0.74 | 0.43 | 0.24–0.77 |
a
AOR for age, BMI, race, degree of insulin resistance, total testosterone, and treatment received during PPCOS II (Clomid vs letrozole). Other AORs are controlled for vitamin D status and all other covariates in the table.